IRLAB Therapeutics: Collaboration bolsters CNS assets and platform - Edison

IRLAB has announced an agreement with the McQuade Center for Strategic Research and Development (MSRD), a member of the Otsuka family of pharmaceutical companies. As part of this agreement, MSRD will evaluate IRLAB’s neuropsychiatric preclinical programmes: IRL757 (apathy) and IRL942 (cognitive function). MSRD searches for, identifies and funds innovative early-stage R&D programmes that it believes have the potential to build the future portfolio of Otsuka products. We view this external interest from MSRD as encouraging for IRLAB’s preclinical portfolio; discussions are expected in coming months regarding a potential R&D collaboration for these programmes.

Länk till analysen i sin helhet: https://www.edisoninvestmentresearch.com/research/company/irlab-therapeutics

Länk till analysen i sin helhet: https://www.edisoninvestmentresearch.com/research/report/irlab-therapeutics827497/preview